New research studies surrounding the medication Retatrutide , specifically the 120mg formulation branded as ZPHC, reveal a considerable effect on body mass reduction and associated health factors. Experts posit that this dual agonist , affecting both GLP-1 and GIP receptors , has the potential to offer a major advance in the management of excess w